Takeda is a patient-focused, values-based, R&D-driven biopharmaceutical company committed to delivering highly innovative medicines and transformative care to improve lives worldwide. Takeda supports the Commissions objectives for the revision of the EU pharmaceutical legislation: the ambition for timely access and enhanced availability of medicines across Member States, more efficient regulatory processes, and an…
TPI
Takeda Pharmaceuticals International AG
Company · Japan · EU Transparency Register 815176718826-78
8
positions filed
in the 665 files tracked
5
legislative files
of 665 tracked
2
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1210 companies & groups on this site, they rank #278 by legislative files engaged, a count of participation, not a measure of influence.
1.8
declared lobbying FTE
self-declared
€1M+
declared costs / yr (floor)
3
EP accreditations
as declared to the register
2015
in the register since
Declares membership of
- Takeda is a member of European Federation of Pharmaceutical Industries and Associations (EFPIA) and Vaccines Europe.
- Takeda is member of EUCOPE (European Confederation of Pharmaceutical Enterpreneurs).
- Takeda is also member of PPTA Europe, Japanese Business Council in Europe and MedTech Europe.
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Companies & groups
- Head office
- Zurich, Switzerland
- EU office
- Brussels
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Takeda in PolicySpeak: request access →
Work at Takeda Pharmaceuticals International AG? so we know who speaks for it.
Their record over time
Takeda Pharmaceuticals International AG filed 8 positions between 14 Dec 2020 and 8 Oct 2026, across 5 of the 665 legislative files tracked here, attaching a full position paper 2 times.
2020 · 1 filed2021 · 2 filed2022 · 1 filed2023 · 2 filed2026 · 2 filed
What they argued
Takeda is a patient-focused, values-based, R&D-driven biopharmaceutical company committed to delivering highly innovative medicines and transformative care to improve lives worldwide. Takeda supports the Commissions objectives for the revision of the EU pharmaceutical legislation: the ambition for timely access and enhanced availability of medicines across Member States, more efficient regulatory processes, and an…
Takeda is a patient-focused, values-based, R&D-driven biopharmaceutical company committed to delivering highly innovative medicines and transformative care to improve lives worldwide. The Covid-19 crisis has shown that Europe needs to reflect on how to deliver resilient health systems whilst remaining a competitive actor on the global stage.
Takeda welcomes the European Commissions proposal for a European Biotech Act and supports its overall ambition to strengthen Europes biotechnology and life sciences ecosystem. The Biotech Act is a positive and necessary step to reinforce Europes position in innovative biotechnologybased medicines.
As a patient-focused, values-based, R&D-driven global biopharmaceutical company, Takeda welcomes the proposal for a new Regulation on Substances of Human Origin (SoHO) and the Commission's efforts to help ensure legislation can respond to new scientific and technical developments while meeting the needs of European patients and safeguarding donor health and safety.
Takeda is a global, patient-focused, values-based and R&D-driven biopharmaceutical company committed to better health and a brighter future. We welcome the initiative to review EU legislation on Blood, Tissues and Cells (BTC) to ensure it considers new scientific and technical developments and includes the necessary provisions to meet donor and patient needs, while ensuring their safety.
Takeda is a global, patient-focused, values-based and R&D-driven biopharmaceutical company committed to bringing better health to people and a brighter future to the world. Takeda believes this review should focus on supporting the sustainable development of innovative therapies addressing unmet medical needs and access pathways for patients to benefit for these therapies in a timely and equitable manner.
Takeda supports the continuation and enhancement of the Autonomous Tariff Suspensions and Quotas (ATSQ) Scheme as a critical instrument for ensuring the competitiveness and resilience of pharmaceutical manufacturing within the European Union.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Takeda Pharmaceuticals International AG next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 107.
Is this your organization?
Everything on this page comes from Takeda Pharmaceuticals International AG’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.